Increasing glutathione levels for therapy
AssigneeBaylor College of Medicine
InventorRajagopal V. Sekhar
Life of this patent
Estimating the term…
Abstract
The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels.
Claims11
A composition:
- (a) consisting essentially of glycine and N-acetylcysteine;
- or
- (b) consisting of glycine and n-acetylcysteine.
A method of reducing deleterious effects of oxidative stress in an individual, comprising the steps of providing an effective amount of glycine and N-acetylcysteine to the individual.
A method of treating diabetes in an individual, comprising the step of providing an effective amount of glycine and n-acetylcysteine to the individual.
A method of treating a medical condition in an individual, wherein the medical condition is associated with reduced glutathione levels, comprising the steps of:
- a) identifying an individual in need of treatment of the medical condition;
- and
- b) providing an effective amount of glycine and N-acetylcysteine to the individual.
A method of increasing GSH levels in an individual in need thereof, comprising the step of providing an effective amount of glycine and n-acetylcysteine to the individual, wherein the individual in need thereof is at least sixty years of age and/or has diabetes.
A method of reducing body weight, lowering cholesterol level, and/or lowering triglyceride level in an individual, comprising the step of providing an effective amount of glycine and n-acetylcysteine to the individual.
A method of treating an individual for one or more medical conditions, comprising the step of providing an effective amount of glycine and n-acetylcysteine to the individual, wherein the medical condition comprises:
- (a) dyslipidemia and/or insulin resistance;
- (b) obesity;
- (c) fatty acid oxidation;
- (d) diabetic dyslipidemia;
- (e) elevated fatty acid levels;
- (f) diabetic microvascular complication comprising nephropathy, retinopathy, and/or neuropathy;
- (g) elevated cholesterol and/or triglyceride levels;
- (h) fatty liver disease;
- (i) neurodegenerative disease in aging;
- and/or
- (j) statin-induced myopathy.
Dependencies are inferred from the claim text.